Associated Papers
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.
Shin JW et al.
Biomolecules, 2019
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.
Petrelli F et al.
Breast Cancer Research and Treatment, 2017
HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.
Wang T et al.
Cancer Science, 2017
Select a paper to view details